|I.||ADHD Advocacy Organizations|
|II.||Selected ADHD Websites|
|III.||Pharmaceutical Industry-Sponsored ADHD Websites|
|V.||Online ADHD Stores|
Attention Deficit Disorder Association is an international non-profit organization for adults with ADHD. The mission of this organization is to provide information, resources, networking and advocacy. On their user-friendly website, there are numerous articles on various topics written for general populations, including organization/time management, women vs. men with ADHD, relationship and family issues, school/career/workplace, ADHD coaching, research and treatment.
Children and Adults with Attention-Deficit/Hyperactivity Disorder (CHADD) is the nation's leading non-profit organization with 20,000 plus members, serving the needs of children and adults with ADHD. CHADD provides evidence-based information to parents, educators, professionals, the media and the general public.
National Resource on ADHD is a program of CHADD established with funding from the U.S. Centers for Disease Control and Prevention (CDC). This is a national clearinghouse of information and resources. New information and updates are posted regularly.
CHADD of Chicago, http://chaddofchicago.tripod.com/
This chapter has support groups and educational programs about ADHD.
ADD/ADHD at About.com provides practical information and articles on motivating teenagers, behavioral therapies for adults with ADHD, ADD coaching, and ADHD treatment.
ADDitude Magazine Online is mainly a collection of articles with current information. Though at the first glance it appears to be tailored to parenting ADHD children, the Adult ADD/LD session has plenty useful tips for job, time and money management, organization, love and friendship; topics pertinent to adult life.
ADDvance is developed and maintained by Kathleen Nadeau, Ph.D., and Patricia Quinn, M.D., both are internationally recognized experts on ADHD. It was originally developed for girls and women with ADHD, later expanded to all people across the life span; nevertheless, the site offers the most useful information for female populations. A related site by the same group is the National Center for Gender Issues and AD/HD at http://www.ncgiadd.org/ The resources session provides multiple links to many useful sites.
AdhdNews is unique for its functioning as an on-line support group with active message boards and blogs.
A free-email newsletter, Attention Research Update, is written by David Rabiner, Ph.D., a research psychologist at Duke University. This newsletter provides updates on ADHD research.
A website from Northern County Psychiatric Associates, a group near Baltimore, provides many accurate and up-to-day articles on ADHD.
All supported by Shire, the maker of Adderall XR, Daytrana and Vyvanse.
Supported by Novartis, maker of Ritalin LA/SR, providing educational information for parents, school personnel, and a program called Straight Talk About Responsible Treatment (S.T.A.R.T.) designed to educated patients and caregivers about appropriate use of stimulant medications.
Supported by McNeil, maker of Concerta.
Coaching Services for Adults with ADD.
A site found and directed by Terry Matien, a psychotherapist and consultant specializing in adult ADHD who also has ADHD herself. The site has a directory for ADHD Professionals and Coaches.
By American Coaching Association, an organization founded with the goal of making individualized coaching available to everyone who desires it.
A website by Nancy Ratey, “a strategic life coach specializing in executives, entrepreneurs, and professionals with ADHD”
Driven to Distraction: Recognizing and Coping with Attention Deficit Disorder from Childhood Through Adulthood, Simon and Schuster 1994, Edward M. Hallowell, M.D. & John J. Ratey, M.D.
One of the first books written for the general public about ADHD. It’s strength lies in it’s vivid descriptions and profiles of the professional, personal. social and occupational lives of those suffering from this disorder. These profiles convey both the overt impairments that make up the formal diagnostic criteria of the disorder along with the more subtle effects on personality, intimacy and self esteem. Many patients first recognize their ADHD through the evocative portraits used in this book. A must read for anyone considering this diagnosis for themselves or loved ones.
Delivered from Distraction, Random House Publishing Group 2005, Edward M. Hallowell, M.D. & John J. Ratey, M.D.
The sequel to the wildly successful bible on ADHD, this second work emphasizes treatment and coping strategies.
You Mean I'm not Lazy, Stupid or Crazy? A Self-Help Book for Adults with Attendtion Deficit Disorder, Scribner 2006, Kate Kelly, Peggy Ramundo, and Larry B. Silver
Very basic but compelling description and explanation about the disorder. Many of my patients love this book.
ADD-Friendly Ways to Organize Your Life, Routledge 2002, Judith Kolberg & Kathleen Nadeau
Out of the Fog: Treatment Options and Strategies for Adult Attention Deficit Disorder, Hyperion 1995, Suzanne LeVert and R. Murphy
A Comprehensive Guide to Attention Deficit Disorder in Adults: Research, Diagnosis and Treatment, Brunner/Mazel 1995, Kathleen Nadeau
Women with Attention Deficit Disorder: Embracing Disorganization at Home and in the Workplace, Underwood Books 1995, Sari Solden
View from the Cliff: A Course in Achieving Daily Focus, Taylor Trade Publishing 2001,
Attention Deficit Disorder in Adults, Taylor Trade Publishing 1997, Lynn Weiss and Kenneth A. Bonnet
Vyvanse: The New Kid on the ADHD Block
ADHD is an increasingly recognized disorder and pharmaceutical companies are regularly developing new drugs and new formulations of older drugs in an attempt to gain an increasing share of this lucrative market. Whether the new pharmaceuticals bring actual therapeutic advantage or simply represent new 'brands' with similar effectiveness is an ongoing question. Vyvanse (Lisdexamfetamine dimesylate) is the newest arrival on this competitive turf. It was shown to be effective compared to placebo in two clinical trials of children ages 6-12 and in one trial in adults.
Vyvanse is a prodrug formulation of dextroamphetamine. A prodrug is a pharmacological substance (drug) that is administered in an inactive (or significantly less active) form. Once administered, the prodrug is metabolized into an active metabolite. In the case of Vyvanse, this process takes place in the gastrointestinal tract, thus releasing active dextroamphetamine. The active metabolite dextroamphetamine then mediates the therapeutic effect in a fashion similar to other stimulants. Though the mode of therapeutic action in Attention-Deficit/Hyperactivity Disorder (ADHD) is not known, the amphetamines are thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these substances in the brain.
Lisdexamfetamine does not produce high dextroamphetamine levels when injected or snorted, and thus may have lower abuse potential compared to conventional stimulants. Vyvanse was developed specifically in this prodrug formulation with the goal of providing an extended duration of effect that is consistent throughout the day, with a reduced potential for abuse, overdose toxicity, and drug tampering. Side effects were consistent with other psychostimulants, and long term monitoring demonstrated no significant changes in blood pressure or electrocardiographic parameters. There have been no comparative studies between Vyvanse and other stimulants, and it's duration of effectiveness is similar to other long acting stimulant formulations (8-10 hours). The only circumstances that Vyvanse seems to be more useful in treatment over other stimulants are those in which there is a significant abuse potential. With the possibility of this rather slender exception, our verdict on Vyvanse is that it is more of the same: another long-acting stimulant in a field that is growing in size but not diversity. We look forward to different drug development strategies, perhaps those which derive from a more precise molecular genetic understanding of the neurobiology of ADHD, that will one day generate truly novel and improved therapeutic agents for this disorder.